Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Status:
Completed
Trial end date:
2018-11-13
Target enrollment:
Participant gender:
Summary
This study will include participants with previously treated systemic relapsed or refractory
light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the
safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib)
administered orally.